1. Home
  2. BWA vs GKOS Comparison

BWA vs GKOS Comparison

Compare BWA & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BorgWarner Inc.

BWA

BorgWarner Inc.

N/A

Current Price

$60.49

Market Cap

12.9B

ML Signal

N/A

Logo Glaukos Corporation

GKOS

Glaukos Corporation

N/A

Current Price

$162.86

Market Cap

10.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BWA
GKOS
Founded
1987
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Auto Parts:O.E.M.
Medical/Dental Instruments
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.9B
10.6B
IPO Year
1995
2015

Fundamental Metrics

Financial Performance
Metric
BWA
GKOS
Price
$60.49
$162.86
Analyst Decision
Buy
Strong Buy
Analyst Count
15
14
Target Price
$79.93
★ $198.69
AVG Volume (30 Days)
★ 1.9M
668.3K
Earning Date
10-29-2026
10-28-2026
Dividend Yield
★ 1.13%
N/A
EPS Growth
★ N/A
N/A
EPS
★ 2.50
N/A
Revenue
★ $14,316,000,000.00
$507,442,000.00
Revenue This Year
N/A
$36.18
Revenue Next Year
$4.51
$22.51
P/E Ratio
$24.44
★ N/A
Revenue Growth
1.63
★ 32.33
52 Week Low
$40.50
$73.16
52 Week High
$78.82
$191.62

Technical Indicators

Market Signals
Indicator
BWA
GKOS
Relative Strength Index (RSI) 39.00 50.50
Support Level $59.59 $145.78
Resistance Level $65.82 $184.68
Average True Range (ATR) 1.75 6.59
MACD -0.24 0.09
Stochastic Oscillator 24.93 69.89

Price Performance

Historical Comparison
BWA
GKOS

About BWA BorgWarner Inc.

BorgWarner is a tier one supplier of turbo and thermal management technologies, drivetrain systems, powerdrive systems, and battery and charging systems mostly to automotive original equipment manufacturers. Its products aim to move a vehicle with as few electrons as possible, resulting in cleaner, cost-optimized, and more-efficient vehicles. Foundational products, the combustion vehicle business, contributes more than 80% to group revenue while BorgWarner transitions to becoming an electric vehicle-centric (e-business) and data center energy management parts supplier. In 2024, 23% of the company's revenue was sourced from Volkswagen and Ford. Revenue is well diversified geographically, with approximately a third each generated in North America, Europe, and Asia.

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Share on Social Networks: